Abrdn PLC United Therapeutics Corp Transaction History

Abrdn PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$228.26 - $319.04 $6.25 Million - $8.73 Million	-27,369 Reduced 97.01%	843 $268,000
Q1 2024 May 08, 2024	SELL	$210.76 - $249.51 $13,488 - $15,968	-64 Reduced 0.23%	28,212 $6.48 Million
Q4 2023 Jan 31, 2024	BUY	$214.88 - $256.94 $6.08 Million - $7.27 Million	28,276 New	28,276 $6.22 Million
Q2 2019 Aug 13, 2019	SELL	$76.06 - $120.81 $3.4 Million - $5.4 Million	-44,730 Closed	0 $0
Q4 2018 Feb 12, 2019	SELL	$101.4 - $128.73 $2,433 - $3,089	-24 Reduced 0.05%	44,730 $4.71 Million
Q3 2018 Nov 13, 2018	BUY	$113.81 - $129.46 $1.83 Million - $2.08 Million	16,039 Added 55.86%	44,754 $5.72 Million
Q2 2018 Aug 09, 2018	SELL	$101.14 - $118.31 $512,577 - $599,595	-5,068 Reduced 15.0%	28,715 $3.25 Million
Q1 2018 May 15, 2018	SELL	$107.21 - $151.94 $3.95 Million - $5.6 Million	-36,865 Reduced 52.18%	33,783 $3.8 Million
Q4 2017 Feb 12, 2018	SELL	$118.58 - $151.28 $93,203 - $118,906	-786 Reduced 1.1%	70,648 $10.5 Million
Q3 2017 Nov 14, 2017	BUY	$114.6 - $136.81 $8.19 Million - $9.77 Million	71,434	71,434 $8.37 Million

672

42.3M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.2B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Abrdn PLC, based on Form 13F filings with the SEC.

Stay updated on Abrdn PLC with notifications on news.